FDA grants priority review to J&J cancer drug for head and neck tumors

July 30, 2026 8:30 AM

Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has granted Priority Review to a supplemental ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found